Theracurmin (Nano-Curcumin) for Stage IV Cancer
Also known as: Nano-curcumin, Highly bioavailable curcumin
Nano-curcumin formulation achieves plasma levels sufficient for NF-κB inhibition relevant to cancer treatment.
Mechanism of Action
Theracurmin delivers curcumin at concentrations inhibiting NF-κB, PI3K/Akt, and STAT3 in tumor tissue. Enhanced bioavailability enables meaningful anti-cancer pharmacology not achievable with standard curcumin.
General mechanism: Nano-encapsulated curcumin with 27x bioavailability. NF-κB inhibitor, anti-amyloid, anti-tau, Nrf2 activator at achievable tissue levels.
Current Evidence
Phase I studies show achievable anti-cancer plasma concentrations. Combination with gemcitabine studied for pancreatic cancer. Enhanced bioavailability resolves historical curcumin limitations.
Clinical Status: Phase I/II with enhanced bioavailability. Pancreatic cancer combination studies.
Safety Profile
Safe. Well-tolerated in clinical trials. Same safety profile as standard curcumin with enhanced absorption.
Key Research Questions
- Does Theracurmin achieve tumor tissue concentrations for NF-κB inhibition?
- Can nano-curcumin enhance chemotherapy efficacy in pancreatic cancer?